metoprolol has been researched along with Hypertrophy, Left Ventricular in 38 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) trial will assess the effect of the angiotensin II (Ang II) receptor blocker, telmisartan, on left ventricular hypertrophy (LVH) compared with the b-blocker, metoprolol, at similar antihypertensive doses." | 9.10 | Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. ( Dahlöf, B; Dietz, R; Friedrich, MG; Knecht, M; Sechtem, U; Unger, T, 2003) |
| "The effects of perindopril and metoprolol on left ventricular hypertrophy (LVH) and function were studied in 47 essential hypertensive patients with LVH." | 9.08 | Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. ( Chen, X; Dai, Z; Hui, Y; Wang, W, 1995) |
| " In this study, we characterised left ventricular thrombospondin-1 and -4 expression in rats treated with a beta-blocker metoprolol during the remodelling process in response to pressure overload and acute myocardial infarction." | 7.76 | Metoprolol treatment lowers thrombospondin-4 expression in rats with myocardial infarction and left ventricular hypertrophy. ( Aro, J; Leskinen, H; Luodonpää, M; Mustonen, E; Ruskoaho, H; Rysä, J; Vuolteenaho, O, 2010) |
| "The Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) trial will assess the effect of the angiotensin II (Ang II) receptor blocker, telmisartan, on left ventricular hypertrophy (LVH) compared with the b-blocker, metoprolol, at similar antihypertensive doses." | 5.10 | Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. ( Dahlöf, B; Dietz, R; Friedrich, MG; Knecht, M; Sechtem, U; Unger, T, 2003) |
| " We compared the effects of captopril and metoprolol on the regression of LV mass and the relation to insulin sensitivity." | 5.09 | Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. ( Isaksson, H; Kahan, T; Malmqvist, K; Ostergren, J, 2001) |
| " Twenty five unmedicated patients with primary hypertension were randomised to initial therapy with either the calcium antagonist, felodipine, or a diuretic and doses titrated to achieve similar levels of blood pressure (BP)." | 5.08 | Assessment of effects of two anti-hypertensive regimens on overall cardiovascular risk. ( Jennings, GL; Korner, P; Laufer, E; Reid, C; Sudhir, K, 1995) |
| "The effects of perindopril and metoprolol on left ventricular hypertrophy (LVH) and function were studied in 47 essential hypertensive patients with LVH." | 5.08 | Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. ( Chen, X; Dai, Z; Hui, Y; Wang, W, 1995) |
| " The curative effect of metoprolol tartrate and valsartan in reversing left ventricular hypertrophy in the group positive for autoantibodies was much better than in the negative group." | 3.80 | Autoantibodies against β1 receptor and AT1 receptor in type 2 diabetes patients with left ventricular dilatation. ( Xu, C; Xu, J; Zhao, L, 2014) |
| " In this study, we characterised left ventricular thrombospondin-1 and -4 expression in rats treated with a beta-blocker metoprolol during the remodelling process in response to pressure overload and acute myocardial infarction." | 3.76 | Metoprolol treatment lowers thrombospondin-4 expression in rats with myocardial infarction and left ventricular hypertrophy. ( Aro, J; Leskinen, H; Luodonpää, M; Mustonen, E; Ruskoaho, H; Rysä, J; Vuolteenaho, O, 2010) |
| " We aimed to verify whether the beta-blocker, metoprolol, and the pure heart-rate-reducing agent, ivabradine, have the same effects on haemodynamic function, ventricular remodeling, and Ca2+ handling in post-myocardial infarction (MI) heart failure in rat." | 3.74 | Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. ( Mackiewicz, U; Maczewski, M, 2008) |
| "With carvedilol treatment, LVMI was lower (p<0." | 2.75 | Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. ( Mei, Z; Xiaozhen, H; Yu, S; Yun, Z, 2010) |
| "Twenty-six men with dilated cardiomyopathy underwent serial echocardiography on days 0 and 1 and months 1 and 3 of either metoprolol (n = 16) or standard therapy (n = 10)." | 2.68 | Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. ( Cigarroa, CG; Eichhorn, EJ; Grayburn, PA; Hall, SA; Marcoux, L; Risser, RC, 1995) |
| "Chronic left ventricular hypertrophy (LVH) is associated with depressed contractile performance, abnormal compliance of the chamber, and ultimately, the development of a left ventricular failure." | 2.68 | [The effect of hypotensive drugs on left ventricular mass and diastolic function]. ( Haczyński, J; Jołda-Mydłowska, B; Spring, A; Witkowska, M, 1995) |
| "The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy)." | 2.41 | [Prevention and treatment of congestive heart failure in diabetic patients]. ( Anguita Sánchez, M, 2002) |
| "Treatment with ivabradine in patients within 2 years after HTX significantly reduced post-transplant heart rate and LV mass and was associated with a superior survival in comparison with patients receiving metoprolol succinate." | 1.48 | Control of cardiac chronotropic function in patients after heart transplantation: effects of ivabradine and metoprolol succinate on resting heart rate in the denervated heart. ( Bruckner, T; Darche, FF; Doesch, AO; Ehlermann, P; Helmschrott, M; Katus, HA; Rahm, AK; Rivinius, R; Ruhparwar, A; Thomas, D, 2018) |
| "Treatment with metoprolol effectively attenuated cardiac hypertrophy and reversed pressure overload induced changes on Dyrk1A and ASF, and alternative splicing of CaMKIIδ (all P < 0." | 1.39 | [Metoprolol attenuates pressure overload-induced myocardial hypertrophy through modulating Dryk1A-ASF-CaMKIIδ signaling pathways]. ( Gu, QQ; Lu, XC; Sheng, HZ; Yao, J; Zhu, JH, 2013) |
| "Hypertension is associated with left ventricular hypertrophy (LVH) and diastolic dysfunction." | 1.35 | Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits. ( Bousquet, PP; Monassier, LJ; Signolet, IL, 2008) |
| "3." | 1.29 | Improvement of cardiovascular effects of metoprolol by replacement of common salt with a potassium- and magnesium-enriched salt alternative. ( Karppanen, H; Laakso, J; Mervaala, EM; Vapaatalo, H, 1994) |
| "To discover whether in hypertensives with left ventricular hypertrophy (LVH) the increased muscle mass will completely regress under antihypertensive treatment and drug dosage can in consequence be reduced." | 1.29 | [Decreasing the antihypertensive dosage during longterm treatment and complete regression of left ventricular hypertrophy]. ( Behr, U; Franz, IW; Ketelhut, R; Tönnesmann, U, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (34.21) | 18.2507 |
| 2000's | 14 (36.84) | 29.6817 |
| 2010's | 10 (26.32) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, J | 1 |
| Wu, C | 1 |
| Cao, J | 1 |
| Wang, L | 2 |
| Rivinius, R | 1 |
| Helmschrott, M | 1 |
| Ruhparwar, A | 1 |
| Rahm, AK | 1 |
| Darche, FF | 1 |
| Thomas, D | 1 |
| Bruckner, T | 1 |
| Ehlermann, P | 1 |
| Katus, HA | 1 |
| Doesch, AO | 1 |
| Davies, DR | 1 |
| Bhatia, S | 1 |
| Geske, JB | 1 |
| Yao, J | 1 |
| Sheng, HZ | 1 |
| Lu, XC | 1 |
| Gu, QQ | 1 |
| Zhu, JH | 1 |
| Nelipa, EA | 1 |
| Salamatina, LV | 1 |
| Urvantseva, IA | 1 |
| Karnysheva, SI | 1 |
| Raĭkovskaia, LR | 1 |
| Rizzi, E | 1 |
| Guimaraes, DA | 1 |
| Ceron, CS | 1 |
| Prado, CM | 1 |
| Pinheiro, LC | 1 |
| Martins-Oliveira, A | 1 |
| Gerlach, RF | 1 |
| Tanus-Santos, JE | 1 |
| Zhao, L | 1 |
| Xu, C | 1 |
| Xu, J | 1 |
| Ye, Y | 1 |
| Gong, H | 1 |
| Wang, X | 1 |
| Wu, J | 1 |
| Wang, S | 1 |
| Yuan, J | 1 |
| Yin, P | 1 |
| Jiang, G | 1 |
| Li, Y | 1 |
| Ding, Z | 1 |
| Zhang, W | 1 |
| Zhou, J | 1 |
| Ge, J | 1 |
| Zou, Y | 1 |
| Champetier, S | 2 |
| Bojmehrani, A | 1 |
| Beaudoin, J | 1 |
| Lachance, D | 3 |
| Plante, E | 3 |
| Roussel, E | 3 |
| Couet, J | 3 |
| Arsenault, M | 3 |
| Xiaozhen, H | 1 |
| Yun, Z | 1 |
| Mei, Z | 1 |
| Yu, S | 1 |
| Mustonen, E | 1 |
| Leskinen, H | 1 |
| Aro, J | 1 |
| Luodonpää, M | 1 |
| Vuolteenaho, O | 1 |
| Ruskoaho, H | 1 |
| Rysä, J | 1 |
| Benedetto, U | 1 |
| Melina, G | 1 |
| Refice, S | 1 |
| di Bartolomeo, R | 1 |
| Roscitano, A | 1 |
| Angeloni, E | 1 |
| Sinatra, R | 1 |
| Anguita Sánchez, M | 1 |
| Friedrich, MG | 1 |
| Dahlöf, B | 1 |
| Sechtem, U | 1 |
| Unger, T | 1 |
| Knecht, M | 1 |
| Dietz, R | 1 |
| Gaudreau, M | 1 |
| Drolet, MC | 2 |
| Kobayashi, M | 1 |
| Machida, N | 1 |
| Mitsuishi, M | 1 |
| Yamane, Y | 1 |
| Binder, WD | 1 |
| Fifer, MA | 1 |
| King, ME | 1 |
| Stone, JR | 1 |
| Campos, LA | 1 |
| Iliescu, R | 1 |
| Fontes, MA | 1 |
| Schlegel, WP | 1 |
| Bader, M | 1 |
| Baltatu, OC | 1 |
| Perrino, C | 1 |
| Naga Prasad, SV | 1 |
| Mao, L | 1 |
| Noma, T | 1 |
| Yan, Z | 1 |
| Kim, HS | 1 |
| Smithies, O | 1 |
| Rockman, HA | 1 |
| Signolet, IL | 1 |
| Bousquet, PP | 1 |
| Monassier, LJ | 1 |
| Maczewski, M | 1 |
| Mackiewicz, U | 1 |
| Sabri, A | 1 |
| Rafiq, K | 1 |
| Seqqat, R | 1 |
| Kolpakov, MA | 1 |
| Dillon, R | 1 |
| Dell'italia, LJ | 1 |
| Papademetriou, V | 1 |
| Narayan, P | 1 |
| Kokkinos, P | 1 |
| Li, QP | 1 |
| Rao, MR | 1 |
| Jennings, GL | 1 |
| Sudhir, K | 1 |
| Laufer, E | 1 |
| Korner, P | 1 |
| Reid, C | 1 |
| Vyssoulis, GP | 1 |
| Kouremetis, MT | 1 |
| Valiouli, MA | 1 |
| Michaelides, AP | 1 |
| Toutouzas, PK | 1 |
| Hall, SA | 1 |
| Cigarroa, CG | 1 |
| Marcoux, L | 1 |
| Risser, RC | 1 |
| Grayburn, PA | 1 |
| Eichhorn, EJ | 1 |
| McDonald, KM | 1 |
| Rector, T | 1 |
| Carlyle, PF | 1 |
| Francis, GS | 1 |
| Cohn, JN | 1 |
| Mervaala, EM | 2 |
| Laakso, J | 2 |
| Vapaatalo, H | 2 |
| Karppanen, H | 2 |
| Spring, A | 1 |
| Haczyński, J | 1 |
| Jołda-Mydłowska, B | 1 |
| Witkowska, M | 1 |
| Hui, Y | 1 |
| Dai, Z | 1 |
| Chen, X | 1 |
| Wang, W | 1 |
| Franz, IW | 1 |
| Behr, U | 1 |
| Ketelhut, R | 1 |
| Tönnesmann, U | 1 |
| Schobel, HP | 1 |
| Langenfeld, M | 1 |
| Gatzka, C | 1 |
| Schmieder, RE | 1 |
| Teräväinen, TL | 1 |
| Malmberg, L | 1 |
| Pörsti, I | 1 |
| Yan, X | 1 |
| Xiao, YB | 1 |
| Grimm, D | 1 |
| Huber, M | 1 |
| Jabusch, HC | 1 |
| Shakibaei, M | 1 |
| Fredersdorf, S | 1 |
| Paul, M | 1 |
| Riegger, GA | 1 |
| Kromer, EP | 1 |
| Malmqvist, K | 1 |
| Kahan, T | 1 |
| Isaksson, H | 1 |
| Ostergren, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study[NCT04397302] | 652 participants (Actual) | Observational [Patient Registry] | 2019-01-13 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metoprolol and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin | 2002 |
12 trials available for metoprolol and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy.
Topics: Administration, Sublingual; Adrenergic beta-Antagonists; Aged; Blood Flow Velocity; Blood Pressure; | 2010 |
Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-C | 2010 |
Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 2003 |
Effects of diltiazem, metoprolol, enalapril and hydrochlorothiazide on frequency of ventricular premature complexes.
Topics: Analysis of Variance; Antihypertensive Agents; Cardiac Complexes, Premature; Diltiazem; Echocardiogr | 1994 |
Assessment of effects of two anti-hypertensive regimens on overall cardiovascular risk.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiovascular Diseases; Cholesterol; Diuretics; Drug Thera | 1995 |
Effect of beta-blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Celiprolol; Double-Blind Method; Echocardiography; Ele | 1995 |
Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade.
Topics: Analysis of Variance; Cardiomyopathy, Dilated; Cross-Over Studies; Double-Blind Method; Echocardiogr | 1995 |
[The effect of hypotensive drugs on left ventricular mass and diastolic function].
Topics: Adult; Aged; Antihypertensive Agents; Calcium Channel Blockers; Diastole; Drug Therapy, Combination; | 1995 |
Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension.
Topics: Adult; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventri | 1995 |
Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Double-Blind Method; Female; Heart | 1996 |
[Clinical study on effect of xinjikang capsule in reversing left ventricular hypertrophy].
Topics: Animals; Antihypertensive Agents; Drugs, Chinese Herbal; Humans; Hypertrophy, Left Ventricular; Male | 1996 |
Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood | 2001 |
25 other studies available for metoprolol and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Fabry disease with early-onset ventricular dilation: A case report.
Topics: Adolescent; Aftercare; alpha-Galactosidase; Angiotensin-Converting Enzyme Inhibitors; Dilatation, Pa | 2020 |
Control of cardiac chronotropic function in patients after heart transplantation: effects of ivabradine and metoprolol succinate on resting heart rate in the denervated heart.
Topics: Adult; Anti-Arrhythmia Agents; Benzazepines; Female; Germany; Heart; Heart Rate; Heart Transplantati | 2018 |
58-Year-Old Asymptomatic Man With Left Ventricular Hypertrophy.
Topics: Adrenergic beta-1 Receptor Antagonists; Dyspnea; Echocardiography; Electrocardiography; Genetic Test | 2019 |
[Metoprolol attenuates pressure overload-induced myocardial hypertrophy through modulating Dryk1A-ASF-CaMKIIδ signaling pathways].
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dyrk Kinases; Hypertrophy, Left Ventric | 2013 |
[A case of diagnosis of asymmetric apical hypertrophic cardiomyopathy of the left ventricle with intraventricular obstruction].
Topics: Diagnosis, Differential; Echocardiography; Female; Heart Septal Defects, Ventricular; Humans; Hypert | 2014 |
β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Antihypertensive Agents; Antioxidants; Benzopyrans; | 2014 |
Autoantibodies against β1 receptor and AT1 receptor in type 2 diabetes patients with left ventricular dilatation.
Topics: Aged; Antihypertensive Agents; Autoantibodies; Biomarkers; Diabetes Mellitus, Type 2; Dilatation, Pa | 2014 |
Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2015 |
Gene profiling of left ventricle eccentric hypertrophy in aortic regurgitation in rats: rationale for targeting the beta-adrenergic and renin-angiotensin systems.
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorti | 2009 |
Metoprolol treatment lowers thrombospondin-4 expression in rats with myocardial infarction and left ventricular hypertrophy.
Topics: Animals; Antihypertensive Agents; Hypertension; Hypertrophy, Left Ventricular; Male; Metoprolol; Myo | 2010 |
Effectiveness of beta-blockade in experimental chronic aortic regurgitation.
Topics: Adrenergic beta-Antagonists; Animals; Aortic Valve Insufficiency; Catecholamines; Cell Size; Chronic | 2004 |
Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Disease Models, Animal; Echocardiography, Dopp | 2004 |
Case records of the Massachusetts General Hospital. Case 26-2005. A 48-year-old man with sudden loss of consciousness while jogging.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Diagnosis, Differentia | 2005 |
Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensinogen; Animals; Animals, Geneticall | 2006 |
Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.
Topics: Adrenergic beta-Antagonists; Animals; beta-Adrenergic Receptor Kinases; Blood Pressure; Blood Vessel | 2006 |
Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cardiomyopathies; Dia | 2008 |
Benefits of long-term beta-blockade in experimental chronic aortic regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2008 |
Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Calcium; Disease Models, Animal; Heart Failure; | 2008 |
Sympathetic activation causes focal adhesion signaling alteration in early compensated volume overload attributable to isolated mitral regurgitation in the dog.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Apoptosis; Cells, Cult | 2008 |
[Effects of calcium antagonists on withdrawal of beta-receptor blockers in rats during left ventricular hypertrophy].
Topics: Animals; Hemodynamics; Hypertrophy, Left Ventricular; Isomerism; Male; Metoprolol; Myocardium; Nifed | 1995 |
Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage.
Topics: Animals; Captopril; Dogs; Hemodynamics; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; M | 1994 |
Improvement of cardiovascular effects of metoprolol by replacement of common salt with a potassium- and magnesium-enriched salt alternative.
Topics: Animals; Blood Pressure; Cerebrovascular Disorders; Eating; Electrolytes; Heart Rate; Hemodynamics; | 1994 |
[Decreasing the antihypertensive dosage during longterm treatment and complete regression of left ventricular hypertrophy].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Echocardiography; Exercis | 1996 |
Cardiovascular and renal effects of the combination of felodipine and metoprolol during a high-salt and a moderate-salt diet in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combin | 1997 |
Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agent | 2001 |